Core Points - The article outlines the regulations and responsibilities of the Audit Committee of Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the need for independent directors and their qualifications [2][4][5] - The Audit Committee is responsible for overseeing financial reporting, internal controls, and external audits, ensuring compliance with relevant laws and regulations [3][6][7] Group 1: Audit Committee Structure - The Audit Committee must consist of directors who are not senior management, with a majority being independent directors [2][4] - Independent directors must have relevant professional knowledge and experience to effectively supervise and evaluate audit work [2][4] - The committee is responsible for proposing the hiring or replacement of external auditors and reviewing their fees and terms [5][6] Group 2: Responsibilities and Authority - The main responsibilities of the Audit Committee include supervising external audits, evaluating internal audits, and reviewing financial information [6][7] - The committee must ensure the accuracy and completeness of financial reports and address any significant issues related to fraud or misrepresentation [6][7] - The committee has the authority to hire independent consultants and legal advisors as needed [10][12] Group 3: Meeting Procedures - The Audit Committee is required to hold at least one regular meeting each quarter and can convene additional meetings as necessary [10][12] - A quorum for meetings requires the presence of at least two-thirds of the committee members [10][12] - Meeting records must be kept for a minimum of ten years, detailing attendance, agenda, and decisions made [11][13]

Core Viewpoint - The document outlines the information disclosure regulations for Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2][3]. Group 1: General Provisions - The company must comply with various laws and regulations, including the Company Law and Securities Law, to ensure proper information disclosure [1]. - Information disclosure is defined as the act of publicly announcing significant information that could impact stock prices, in accordance with regulatory standards [3]. - The company and its information disclosure obligors must ensure that disclosed information is truthful, accurate, complete, and easily understandable [2][4]. Group 2: Information Disclosure Obligations - The company must disclose all information that could significantly affect stock prices or investment decisions, including major events and financial performance [9][10]. - Information disclosure must be conducted fairly, ensuring all investors have equal access to information without any selective disclosure [2][4]. - The company is required to report any major events that may not meet the legal disclosure standards but could still impact stock prices [4][9]. Group 3: Reporting Procedures - The company must follow a structured process for drafting, reviewing, and disclosing periodic reports, which include quarterly, semi-annual, and annual reports [13][14]. - Major events must be disclosed immediately, detailing the cause, current status, and potential impact on the company [28]. - The board of directors is responsible for ensuring that all disclosures are accurate and timely, with specific roles assigned to the board secretary and other management personnel [22][23]. Group 4: Internal Reporting and Compliance - The company has established internal reporting mechanisms to ensure that all significant information is communicated to the board in a timely manner [39][40]. - Directors and senior management are responsible for monitoring and reporting any significant changes in the company's operations or financial status [61][62]. - The company must maintain confidentiality regarding undisclosed information and ensure that all personnel comply with these confidentiality requirements [76][77].

General Overview - The document outlines the information disclosure management system for Jiangsu Kangwei Century Biotechnology Co., Ltd, focusing on the procedures for deferring and exempting information disclosure obligations [2][3]. Information Disclosure Deferral and Exemption - The company can defer or exempt information disclosure without applying to the Shanghai Stock Exchange if the information falls under specific conditions outlined in the listing rules [3]. - Information that involves trade secrets or confidential business information can be deferred or exempted if it meets certain criteria, such as potential harm to the company or others if disclosed [3][4]. Criteria for Deferral and Exemption - The criteria for deferring or exempting disclosure include: 1. Disclosure of core technology information that may lead to unfair competition. 2. Disclosure of operational information that could infringe on the commercial secrets of the company or third parties. 3. Other situations where disclosure could severely harm the interests of the company or others [3][4]. Responsibilities and Procedures - The company must maintain strict confidentiality regarding state secrets and cannot use the excuse of confidentiality to promote business [3][4]. - A mechanism for accountability is established for any failure to report deferral or exemption matters in a timely manner, with potential penalties for responsible individuals [4][5]. Documentation and Record-Keeping - The company is required to keep detailed records of any deferral or exemption actions, including the reasons and internal review processes, for a minimum of ten years [4][5]. - Specific forms and documentation are outlined for the approval process of deferring or exempting disclosures, including a confidentiality commitment from individuals aware of the information [5][8].

Core Viewpoint - The company intends to increase the use of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund utilization and maximize shareholder returns while ensuring the safety of the raised funds and the implementation of investment projects [1][5][7]. Summary by Sections Fundraising Basic Situation - The company was approved for its initial public offering (IPO) on November 27, 2020, with a total of 48.676088 million shares issued at a price of RMB 43.22 per share, raising a total of RMB 2,103.7805 million. After deducting issuance costs, the net amount raised was RMB 1,942.3216 million [1]. Fund Investment Project Basic Situation - The total planned investment for the projects funded by the raised capital is RMB 1,355.8911 million, with the same amount allocated for fundraising [2]. Previous Use of Idle Funds for Cash Management - The company previously approved the use of up to RMB 880 million of temporarily idle funds for cash management, allowing for the purchase of safe, liquid financial products. This approval is valid for 12 months from the board's decision [2][3]. Current Increase in Cash Management Usage - The company plans to increase the cash management limit by RMB 60 million, bringing the total to RMB 940 million. This increase is also valid for 12 months from the board's approval [4][6]. Investment Purpose - The aim is to rationally utilize temporarily idle funds for cash management to improve fund efficiency and increase returns for shareholders, without affecting the implementation of investment projects [3][5]. Investment Products - The company will invest in high-safety, principal-protected, and liquid products, including but not limited to guaranteed financial products, structured deposits, large certificates of deposit, and time deposits [4]. Implementation and Disclosure - The company’s chairman is authorized to make investment decisions within the approved limits, and the finance department will organize the implementation. The company will comply with relevant disclosure obligations [4][5]. Impact on the Company - The increase in cash management usage will not affect the normal operation of the company’s funds or the implementation of investment projects, and it is expected to generate additional investment returns for the company and its shareholders [5][7]. Review Procedures and Opinions - The board and supervisory committee have approved the increase in cash management usage, confirming that it aligns with legal requirements and does not harm the interests of the company or minority shareholders [6][7].

中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人民币9581.5万元， 同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

智通财经APP讯，中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人 民币9581.5万元，同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

Group 1 - The core viewpoint of the article highlights Tianyu Bio's strong performance in the first half of 2025, achieving a revenue of 412 million yuan and a net profit of 10.818 million yuan, representing a year-on-year growth of 73.68% [1] - The company is focusing on a "digital transformation" strategy to enhance quality and efficiency, actively embracing applications of artificial intelligence and optimizing resource allocation for the ecological agriculture and energy sectors [1] - In the ecological livestock business, the company sold 204,214 pigs, a year-on-year increase of 21.52%, generating 312 million yuan in revenue, which is a 17.49% increase compared to the previous year [1] Group 2 - The company is developing a series of red yeast products and health foods, positioning healthy ecological food as a strategic breakthrough to support its ecological agriculture strategy [2] - The production capacity of red yeast products increased by 36.78 tons year-on-year, with sales revenue rising by 734.95 thousand yuan [2] - In the ecological energy sector, the company has made progress in expanding its business, signing contracts for distributed photovoltaic power generation projects, achieving a green power revenue of 14.8976 million yuan from 6.30 MW of projects connected to the grid [2]

证券代码：688289 证券简称：圣湘生物 公告编号：2025-060 关于 2025 年半年度募集资金存放与实际使用情 况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证监会发布的《上市公司募集资金监管规则》和上海证券交易所发布的 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定， 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）董事会编制了截至 2025 年 6 月 30 日止的《关于 2025 年半年度募集资金存放与实际使用情况的专项报告》， 具体说明如下： 一、募集资金基本情况 （一）实际募集资金金额、募集完成时间 根据中国证券监督管理委员会《关于同意圣湘生物科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2020]1580 号），本公司于 2020 年 8 月向社会公众 公开发行人民币普通股 40,000,000 股。每股面值为人民币 1.00 元，每股发行价为人民 币 50.48 元，募集资金总额为人民币 2,019,200,000.00 元 ...

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to HKD 77.0, indicating a potential upside of 16% from the current price of HKD 66.5 [2][5][7]. Core Insights - The company's net loss attributable to shareholders for the first half of 2025 was better than expected, with revenue reaching RMB 499 million, a year-on-year increase of 812.1%. Product revenue was RMB 169 million, while collaboration revenue was RMB 329 million, up 502.6% year-on-year [5][7]. - The company is focusing on the commercialization of CM310 and preparing for national medical insurance negotiations, with confidence in multiple indications being included in the insurance scheme [5][7]. - The next-generation core pipeline drug, CM512, is being prioritized for development, showing promising safety and efficacy in preclinical studies [5][7]. Financial Performance - For 1H25, the company reported a net loss of RMB 78.84 million, significantly reduced from RMB 337 million in 1H24, primarily due to better-than-expected collaboration revenue and improved gross margins [5][7]. - The company’s cash position improved to RMB 2.8 billion as of June 30, 2025, up from RMB 2.16 billion at the end of 2024, aided by a successful placement in June [5][7]. - Revenue projections for the upcoming years show significant growth, with expected revenues of RMB 823 million in 2025, RMB 1.5 billion in 2026, and RMB 2.3 billion in 2027, reflecting year-on-year growth rates of 92%, 82%, and 54% respectively [7][9].

Group 1 - A biotech company in Jiangsu with a market value of over 10 billion HKD is seeking a securities representative [1] - The job responsibilities include organizing meetings, information disclosure, securities work, corporate governance, and compliance related to listing [1] - The ideal candidate should have at least 5-8 years of experience in listed companies (including Hong Kong stocks) or law firms in capital markets [1] Group 2 - "Ju Dong Mi" aims to create a benchmark evaluation for listed companies and serve as an important reference for talent selection in the industry [4] - The evaluation is the first to select board secretaries from A-shares, Hong Kong stocks, and Chinese concept stocks simultaneously, making it one of the largest evaluations in the domestic market [4] - The 2023 evaluation involved sending invitations to over 2000 prospective/listed companies and conducting a preliminary selection of over 500 candidates, with more than 16,000 industry professionals and analysts participating in the voting process [4]